Get the latest news, insights, and market updates on PRAX (Praxis Precision Medicines, Inc.). Explore the news page 7 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on November 3, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 6,876 shares of its common stock to six Nov 6, 2025 - $PRAX
High Growth Tech Stocks In The US Market November 2025
In the midst of a volatile U.S. market, where concerns about AI valuations have led to fluctuations in major indices like the Dow Jones and Nasdaq, investors are closely watching earnings reports and economic indicators amid a historic government shutdown. As tech stocks face renewed scrutiny, identifying high-growth opportunities requires careful consideration of companies' adaptability to current trends and their potential for innovation in an uncertain economic landscape. Nov 6, 2025 - $PRAX
Compounding Losses Challenge Bullish Profit Growth Narratives at Praxis Precision Medicines (PRAX)
Praxis Precision Medicines (PRAX) is forecast to reach profitability within the next three years, with earnings projected to grow at 67.85% per year and revenue expected to expand by 70.8% per year, both well above market averages. Despite these forward-looking projections, the company currently remains unprofitable, with losses compounding at a rate of 12% per year over the last five years. At a share price of $164.64, PRAX trades below its discounted cash flow fair value estimate of... Nov 6, 2025 - $PRAX
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA scheduled for Q4 2025 Plans to accelerate the development of relutrigine in SCN2A and SCN8A DEE patients after comprehensive Type B meeting with FDA Recruitment completed for POWER1 study of vormatrigine in focal onset seizures, with topline results expected in 1H 2026 POWER2 study started, with enrollment expected to complete in 2H 2026 Pro forma cash a Nov 5, 2025 - $PRAX
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation inhibition imbalance, announced it will be attending and presenting at the following upcoming investor events: Truist Securities BioPharma Symposium: a corporate presentation will take place on Thursday, November 6, 2025, a Nov 5, 2025 - $PRAX
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy Designation Key aspects of a potential NDA application discussed and aligned with the Agency Praxis plans to perform an interim analysis of the EMBOLD cohort 2 pivotal trial in Q4 2025, which if positive should serve as the basis of an NDA in early 2026 BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insi Nov 4, 2025 - $PRAX
Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the 12 Best Performing Stocks in the Last 3 Months. On October 16, Oppenheimer raised its price target on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) from $115 to $250 and kept an Outperform rating. This decision came after positive topline results from Praxis Precision Medicines, Inc.’s (NASDAQ:PRAX) 3 […] Nov 3, 2025 - $PRAX
Is Praxis Precision Medicines Worth a Closer Look After 261.8% Surge on Trial Results?
If you have been paying any attention to Praxis Precision Medicines lately, you have probably noticed the ticker’s rollercoaster ride. Over the past week alone, shares have skyrocketed by an astonishing 261.8%. Zoom out to 30 days, and that number jumps even higher to 350.1%. For anyone who has been holding since the start of the year, Praxis is up 139.0%, and over the past year, it boasts a 163.0% return. However, the company’s journey hasn’t been all upside. Looking back five years, the... Oct 22, 2025 - $PRAX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple